Amneal Pharmaceuticals Inc. (AMRX) exhibits 36.9% gross margins and 14.1% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 21.4x enterprise multiple and 4.8% implied options volatility.
Sustained 36.9% gross profitability converts into 13.1% operating margin and 14.1% ROIC, outpacing sector cost of capital.
ROIC: 14.1% // GM: 36.9%YoY revenue trajectory of +8.0% paired with 3.63% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +8.0% // FCF YLD: 3.63%Altman Z-Score of 3.83 and Piotroski F-Score of 9/9 indicate low near-term refinancing stress.
ALTMAN Z: 3.83 // F-SCORE: 9/9Trading at 103.2x trailing P/E (96.0x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 103.2x // EV/EBITDA: 21.4xOptions market prices a ±5.2% implied move with a 0.85 put/call ratio around $20.44 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend 2.4% net margins.
NET MARGIN: 2.4% // D/E: 0.85x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for AMRX & activate live FRED threshold breach alerts.